Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus casei DG for prevention of Crohn's disease relapse after antibiotic-induced remission
2005-002418-39Phase 3Active
- Sponsor
- SOFAR
- Start
- Jan 2007
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Lactobacillus casei DG (Enterolactis Plus) with Placebo (2 arms). Started Jan 2007; status: active.
02
Drugs
lactobacillus casei DG
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2005-002418-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002418-39.